Twist Bioscience and Astellas have entered into a research collaboration and exclusive option license agreement to identify potential therapeutic antibodies which would help to reduce tumor microenvironment-mediated immunosuppression.

Genome sequencing group Illumina on March 15 launched a cancer test in Europe that checks for a wide range of tumor genes in one tissue sample, potentially helping patients with rare diseases to be matched up with treatment options.

Loxo Oncology struck a deal with Bayer AG to develop and commercialize two cancer therapies worth up to $1.55 billion.